Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma

Pavlos Msaouel(The University of Texas MD Anderson Cancer Center), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center)

Cancer Cell

April 30, 2020

10.1016/j.ccell.2020.04.002

Cited by 140

Related Papers

Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence

|Nature Communications|2025|4